Login to Your Account

Cayston Nod a Small Win for Gilead Ahead of New HIV Data

By Jennifer Boggs

Wednesday, February 24, 2010
Gilead Sciences Inc.'s ongoing strategy to diversify its pipeline scored a small victory with the approval of inhaled aztreonam lysine drug Cayston, but there's no question the firm's future growth still hinges largely on its next-generation HIV pipeline. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription